Search
MT-0169
go.drugbank.com/drugs/DB17430InvestigationalMT-0169 is a usion protein comprised of an enzymatically active Shiga-like toxin-I A1 subunit fused to a human single chain variable fragment with affinity for human CD38 cell surface protein.
AMP-101
go.drugbank.com/drugs/DB18253ExperimentalAMP-101 is a gene therapy comprising an adeno-associated virus type 9 (AAV9) vector encoding the human Dok-7 protein. It is under investigation for the treatment of Dok-7-associated myasthenia.
EGT-101
go.drugbank.com/drugs/DB17645ExperimentalDeveloped by Esteve Pharmaceuticals, it is being investigated for Sanfilippo syndrome type A.[L45919] … EGT-101 is an adeno-associated viral vector serotype 9 (AAV9) vector-based gene therapy consisting of the human sulfamidase (SGSH) transgene.
XC221
go.drugbank.com/drugs/DB16503InvestigationalXC221 was investigated in clinical trials to treat patients with respiratory infections, including influenza, COVID-19, and other acute viral upper respiratory infections.
Categories: Experimental Unapproved Treatments for COVID-19Ruplizumab
go.drugbank.com/drugs/DB06475InvestigationalRuplizumab is a humanized monoclonal antibody used as an immunosuppressive drug and is a component of Antova.
Ohmefentanyl
go.drugbank.com/drugs/DB01570ExperimentalIllicitOhmefentanyl is one of the most potent μ -receptor agonists known, comparable to super-potent opioids such as carfentanil and etorphine which are used for tranquilizing large animals such as elephants … Ohmefentanyl is an extremely potent opioid analgesic drug which selectively binds to the µ-opioid receptor. The Chinese have recorded ohmefentanyl as having a potency that is 6,300 times morphine.
Liposomal prostaglandin E1
go.drugbank.com/drugs/DB05391InvestigationalLiposome-encapsulated form of prostaglandin E1 (Liprostin) is known to be a potent vasodilator and platelet inhibitor as well as an anti-inflammatory and anti-thrombotic agent.
XPro1595
go.drugbank.com/drugs/DB16454InvestigationalXPro1595 is an investigational dominant-negative protein that neutralizes soluble TNF.
Categories: Experimental Unapproved Treatments for COVID-19Etifoxine
go.drugbank.com/drugs/DB08986ApprovedWithdrawnIt does not bind to the benzodiazepine receptor though the effects are similar to that of benzodiazepines. It is more effective than lorazepam as an anxiolytic, and has fewer side effects. … Etifoxine is an anxiolytic and anticonvulsant drug developed by Hoechst in the 1960s. It is used in anxiety disorders and to promote peripheral nerve healing.
Triazolam
go.drugbank.com/drugs/DB00897ApprovedInvestigationalWithdrawn in the United Kingdom due to risk of psychiatric adverse drug reactions. This drug continues to be available in the U.S. Internationally, triazolam is a Schedule IV drug under the Convention on Psychotropic Substances.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates